Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has granted 11,847 restricted stock units (RSUs) to a new employee. The RSUs will vest in four equal annual installments over four years, contingent upon continued employment. The grant was made under the Company's 2024 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Solid Biosciences (Nasdaq: SLDB), un'azienda nel settore delle scienze della vita che si concentra sullo sviluppo di farmaci genetici di precisione per le malattie neuromuscolari e cardiache, ha concesso 11.847 unità azionarie vincolate (RSU) a un nuovo dipendente. Le RSU verranno assegnate in quattro rate annuali uguali nell'arco di quattro anni, condizionatamente all'impiego continuato. La concessione è avvenuta nell'ambito del Piano di Incentivazione Azionaria 2024 dell'azienda e rispetta la Regola di Quotazione Nasdaq 5635(c)(4) come incentivo all'impiego.
Solid Biosciences (Nasdaq: SLDB), una empresa de ciencias de la vida centrada en el desarrollo de medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, ha otorgado 11,847 unidades de acciones restringidas (RSUs) a un nuevo empleado. Las RSUs se concederán en cuatro partes anuales iguales durante cuatro años, condicionadas a la continuación del empleo. La concesión se realizó bajo el Plan de Incentivos de Acciones 2024 de la empresa y cumple con la Regla de Cotización de Nasdaq 5635(c)(4) como un incentivo de empleo.
솔리드 바이오사이언스 (Nasdaq: SLDB)는 신경근 및 심장 질환을 위한 정밀 유전 의학 개발에 집중하는 생명 과학 회사로, 새로운 직원에게 11,847개의 제한 주식 단위(RSU)를 부여했습니다. RSU는 고용이 지속되는 조건으로 4년 동안 연간 4회 동등하게 지급됩니다. 이번 부여는 회사의 2024년 유인 주식 인센티브 계획에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유인을 준수합니다.
Solid Biosciences (Nasdaq: SLDB), une entreprise de sciences de la vie spécialisée dans le développement de médicaments génétiques de précision pour les maladies neuromusculaires et cardiaques, a accordé 11.847 unités d'actions restreintes (RSUs) à un nouvel employé. Les RSUs seront acquises en quatre versements annuels égaux sur quatre ans, sous réserve de l'emploi continu. La concession a été faite dans le cadre du Plan d'Incitation à l'Action 2024 de l'entreprise et est conforme à la Règle de Cotation Nasdaq 5635(c)(4) en tant qu'incitation à l'emploi.
Solid Biosciences (Nasdaq: SLDB), ein Unternehmen im Bereich der Lebenswissenschaften, das sich auf die Entwicklung präziser genetischer Medikamente für neuromuskuläre und kardiovaskuläre Erkrankungen konzentriert, hat 11.847 restricted stock units (RSUs) an einen neuen Mitarbeiter gewährt. Die RSUs werden in vier gleichen jährlichen Raten über vier Jahre angerechnet, vorausgesetzt, die Anstellung bleibt bestehen. Die Gewährung erfolgte im Rahmen des 2024 Inducement Stock Incentive Plans des Unternehmens und entspricht der Nasdaq-Listing-Regel 5635(c)(4) als Beschäftigungsanreiz.
- None.
- None.
CHARLESTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee’s continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
How many RSUs did Solid Biosciences (SLDB) grant in December 2023?
What is the vesting schedule for Solid Biosciences (SLDB) December 2023 RSU grant?
Under which plan did Solid Biosciences (SLDB) issue the December 2023 RSU grant?
